Extracellular Vesicle Therapy for Type 1 Diabetes

Setareh Soltani, Kamran Mansouri, Mohammad Sajad Emami Aleagha, Narges Moasefi, Niloofar Yavari, Seyed Kazem Shakouri, Sara Notararigo, Ali Shojaeian, Flemming Pociot, Reza Yarani


Type 1 diabetes (T1D) is a chronic disorder characterized by immune-mediated destruction of pancreatic insulin-producing β-cells. The primary treatment for T1D is multiple daily insulin injections to control blood sugar levels. Cell-free delivery packets with therapeutic properties, extracellular vesicles (EVs), mainly from stem cells, have recently gained considerable attention for disease treatments. EVs provide a great potential to treat T1D ascribed to their regenerative, anti-inflammatory, and immunomodulatory effects. Here, we summarize the latest EV applications for T1D treatment and highlight opportunities for further investigation.

Original languageEnglish
Article number865782
JournalFrontiers in Immunology
Pages (from-to)865782
Publication statusPublished - 8 Apr 2022


  • Diabetes Mellitus, Type 1/therapy
  • Extracellular Vesicles
  • Humans
  • Immunomodulation
  • Insulin
  • Insulin-Secreting Cells


Dive into the research topics of 'Extracellular Vesicle Therapy for Type 1 Diabetes'. Together they form a unique fingerprint.

Cite this